The Bull Rankings scorecard — our quality-growth score is 75.8 / 100, built from three pillars scored 0–100: Quality 80, Growth 73, Value 75 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 14% next year, then recovering toward 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Genpact’s current price of $35.27 sits on the cheap side of its sector peers, reflected in a Value score of 75. That alone would not make the case, but when paired with a Quality score of 80 and a Growth score of 73, the picture sharpens: the business is fundamentally sound, its returns on capital are high, and the upside is not buried under an over‑ambitious valuation. The strongest pillar—Quality—anchors the case. A 22.4 % ROE and an 11.1 % profit margin demonstrate that Genpact extracts solid returns from its capital base, while the modest debt‑to‑equity of 0.54 keeps leverage in check. A beta of 0.58 means the stock has moved less than the market as a whole.
The weakest pillar, Growth, is still a solid 73. It tells us that revenue expansion is steady but not explosive. The 6.5 % YoY revenue growth in the trailing twelve months confirms this. Separately, the reverse‑DCF shows the market pricing in a decline, not a surge. That is a conservative stance that leaves room for upside if the business can sustain or accelerate its growth trajectory.
What the business actually is
Genpact delivers digital transformation, business process management, technology, data, analytics, and AI services to enterprises across India, Asia, North and Latin America, and Europe. Its Financial Services segment is its largest, offering end‑to‑end solutions: customer onboarding, service, collections, loan operations, payment operations, mortgage origination and servicing, compliance, wealth management, capital market support, financial crime and risk management, proprietary insurance policy suite, underwriting support, new business processing, policy administration, customer claims management, and more. These services are sold to large financial institutions that need to modernize legacy systems and comply with tightening regulations. The breadth of the offering and the depth of integration with clients’ core operations create a high switching cost and a recurring revenue stream that fuels Genpact’s revenue engine.
Why it can (or can't) keep compounding
The durability of Genpact’s moat lies in its deep integration with clients’ core banking and risk functions. Once a client embeds Genpact’s processes, the cost of switching rises sharply, and the client’s operational efficiency improves. This creates a virtuous cycle: higher margins feed back into the ability to invest in technology and talent, which in turn drives further client retention and expansion. The company’s free‑cash‑flow of $572 m and ROE of 22.4 % demonstrate that it can generate cash efficiently and return it to shareholders. The “Buying back stock” signal from our model shows the share count shrinking, which lifts earnings per share even when revenue grows slowly.
Compounding is further supported by the “Durable high returns” signal. Genpact’s operating model is built on long‑term client relationships and a technology platform that scales across geographies. Competitors would need to replicate not only the technology stack but also the institutional knowledge and regulatory expertise that Genpact has accumulated over decades. The cost of building such an ecosystem from scratch is prohibitive, giving Genpact a sustainable competitive advantage.
The valuation question
At a P/E of 10.5, Genpact trades at a discount to its peers, though the PEG of 1.16 says the multiple is roughly in line with the earnings growth analysts expect. What makes the price look pessimistic is the reverse‑DCF: it implies cash flow shrinking while revenue still grows. If Genpact can maintain or modestly improve its revenue growth, the current valuation would be a bargain. Conversely, if growth stalls outright, the market’s gloomy assumption would look justified.
The current price of $35.27 sits well below the analyst consensus 1‑year target of $42.18 and within the $31–$58 target range of 11 analysts. Over the past year the stock has traded between $26.85 and $48.64. The “Raising its dividend” signal shows the payout growing at a double‑digit pace.
The bear case
The most compelling skeptic’s argument is that Genpact’s growth is already softening. The reverse‑DCF implied growth of –14 % in year 1 is a concrete signal that the market expects a contraction in free‑cash‑flow growth. If revenue growth were to dip below the current 6.5 %, the company would struggle to maintain its 11.1 % profit margin and 22.4 % ROE. A decline in margin would erode the cash cushion that fuels dividends and share buybacks, potentially forcing the company to cut returns to shareholders. Confirmation would be the buyback slowing or dividend growth stalling, with cash going to shore up operations instead.
What would change our mind
- Revenue growth falling below 6.5 %: If the next quarter’s revenue growth dips under 6.5 %, the gap between what the business delivers and what the price assumes would close, and the discount would look deserved.
- Profit margin slipping below 11.1 %: A margin decline would signal rising costs or pricing pressure, eroding the company’s ability to generate free cash flow and pay dividends.
- Debt‑to‑equity rising above 0.54: An increase in leverage would raise financial risk, especially if the company needs to refinance debt in a tightening credit market.
If any of these thresholds are breached, the balance of evidence would tilt toward a bearish stance, and the current price would no longer justify the implied upside.